Web Results

www.law360.com/articles/801453/chelsea-therapeutics-settles-investor-class-action-for-5-5m

May 27, 2016 ... Chelsea Therapeutics International Inc. has agreed to pay $5.5 million in cash to settle an ... The case is Roman Zak and Cameron McIntyre v.

securities.stanford.edu/filings-documents/1052/CTIL00_01/2014530_f01c_14CV00687.pdf

Jul 1, 2014 ... similarly situated holders of Chelsea Therapeutics International, Ltd. ("Chelsea" ... 2014, that the Board had agreed to sell Chelsea to Lundbeck ...

www.wsgr.com/WSGR/DBIndex.aspx?SectionName=attorneys/BIOS/3988.htm

Rambus, Inc., In re VISX, In re Read-Rite, Israni v. ... Kenneith Klein, et al., The Recorder (California Court of Appeals); and In re Guidant (Indiana Supreme Court). ... LLC; C-Cube Microsystems, Inc. Chelsea Therapeutics International, Ltd.

www.ncbi.nlm.nih.gov/pmc/articles/PMC4207713

Jun 10, 2014 ... Indeed, Laurens et al. ... In a study by Yoshizumi et al. ..... from FES with later onset only in Global Assessment of Functioning scores (40.7 vs. .... individuals who have limited insight into their symptoms, both current and past. .... from Glaxo Smith Kline, Pfizer, Inc., Neuren, Roche, and Seaside Therapeutics.

www.ncbi.nlm.nih.gov/pmc/articles/PMC5073067

Tuberculosis remains a risk to global public health, with 9.6 million new cases of .... pulmonary disease that was grossly limited to the left lower lung (Figure 4 A), with .... Via LE, Kim Y, Marriner G, Dartois V, Scanga C, Janssen C, Wang J, Klein E, Cho ... PET/CT imaging reveals a therapeutic response to oxazolidinones in ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC3772672

Oct 27, 2011 ... The 'limited-sobriety' group included subjects with ≤4 consecutive ... according to International Conference on Harmonization guidelines. ..... 45.8% in the atomoxetine group and 57.3% vs. .... Cephalon, NIDA, Chelsea Therapeutics, and Organon; served on ... Mannuzza S, Klein RG, Bonagura N, et al.

www.ncbi.nlm.nih.gov/pmc/articles/PMC5054781

Dec 23, 2015 ... However, to date mucosal immunization has had limited successes, with issues of ... sites is to develop effective mucosal adjuvants, reviewed by Newsted el al. ..... of The Convention on International Trade in Endangered Species (CITES). ..... Keler T, Green J, Riggs R, He LZ, Ramakrishna V, Vitale L, et al.

www.sec.gov/comments/s7-40-10/s74010.shtml

21, 2014, Chair Mary Jo White response to Mike Crapo, U.S. Senator, et al. ... 17, 2012, William Quam, Managing Director, Nordic Sun Worldwide Ltd., Kigali, Rwanda ... 27, 2012, Corinna Gilfillan, Head of U.S. Office, Global Witness ... 7, 2012, Carolyn T. Israel, M.C.A.T., Nat'l Certification Board for Therapeutic Massage ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2779006

Global anhidrosis refers to widespread anhidrosis greater than 80% of the total body surface area. ... Preganglionic vs postganglionic determination. .... Inc.; and receives research support from Chelsea Therapeutics and from the NIH [ P50NS32352 (PI)] and from the Department of ... Klein CM, Vernino S, Lennon VA, et al.